New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposi...( Data with investigational Taxotere(R...),Health

Data with investigational Taxotere(R) regimens in the management of breast

cancer, across several disease stages, to be presented

BRIDGEWATER, N.J., Dec. 7 /PRNewswire-FirstCall/ -- Among the 62 oral abstracts accepted for presentation at the 30th annual San Antonio Breast Cancer Symposium (SABCS), six with Taxotere(R) (docetaxel) Injection Concentrate investigational regimens will be presented in plenary sessions.

-- Plenary Lecture 1 on the opening day of the symposium will review data

for systemic adjuvant therapies being investigated for the treatment

of breast cancer.

"The worldwide overview: New results for systemic adjuvant therapies." Peto R, Early Breast Cancer Trialists' Collaborative Group (EBCTCG), University of Oxford, UK.

Thursday, December 13, 2007, 8:55 AM / Plenary lecture 1, Exhibit Hall D

-- The data from studies with Taxotere(R)-based regimens and

anthracycline-based regimens will be discussed through two

presentations:

Abst 12: "Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735." Jones S, et al; US Oncology Research, Inc., Houston, TX.

Thursday, December 13, 2007, 9:45AM / Plenary lecture 1, Exhibit Hall D

This presentation includes the updated analysis (seven years median

follow-up) of a randomized trial comparing four cycles of a standard

anthracycline regimen, doxorubicin/cyclophosphamide (AC), to a non

anthracycline regimen, Taxotere(R)/cyclophosphamide (TC). New

findings regarding overall survival as well as the effect of age on

efficacy and safety will be presented.

Abst 13: "Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease." Slamon DJ, et al; Cancer International Research Group (CIRG), Edmonton, AB, Canada.

Thu
'/>"/>